Sanofi, Amgen get solid FDA reviews on PSCK9 meds; J&J files for cancer med approval;

> Sanofi ($SNY) and Regeneron's ($REGN) anticholesterol drug Praluent effectively lowers "bad" LDL cholesterol and is reasonably well-tolerated, FDA staff reviewers said ahead of a Tuesday advisory panel meeting on the drug. Report

> Amgen's ($AMGN) PCSK9 cholesterol fighter Repatha lowered LDL with no red-flag safety problems, FDA staffers concluded in a review before Wednesday's advisory committee meeting on the med. Report

> Johnson & Johnson ($JNJ) said it applied for FDA approval for the "breakthrough"-designated blood cancer drug daratumumab, developed with Genmab. Report

> An FDA panel of experts backed approval of a controversial women's libido pill from Sprout, on the condition that the agency require postmarketing safety studies. Report

> London-based Four Communications snapped up the healthcare agency MSA Media--which counts Novartis ($NVS) and Bayer among its clients--to bolster its media-planning capabilities in the field. Report

And Finally... Botulinum toxin injections, sold as Botox and other brands, could be effective in two forms of neuropathy, a pain journal study found. Report